Pharmaceutical

Neurona raises $102m to advance cell therapy for drug-resistant epilepsy

Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant epilepsy.

Apr 4, 2025 - 06:00
Neurona raises $102m to advance cell therapy for drug-resistant epilepsy
Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant epilepsy.
Read the original article

Tags:

Previous Article

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions

Next Article

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ImPact enters partnership for pathologic myopia therapy development

ImPact enters partnership for pathologic myopia therapy...

Aug 14, 2023

Physicians highlight need for improved non-opioid treatments for opioid use disorder

Physicians highlight need for improved non-opioid treat...

Sep 28, 2024

Opinion: Checklists to screen for patients’ social needs aren’t helping

Opinion: Checklists to screen for patients’ social need...

May 23, 2023